

Form PTO-1449 U.S. Department of Commerce

(REV. 8-83) Patent and Trademark Office

Atty. Docket No.
ENZ-64(D2)

Serial No. 10/733,686

INFORMATION DISCLOSURE CITATION
(use several sheets if necessary)

Applicants: Ilan, et al

Filed: Dec. 10, 2003

Group: Not yet assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPRO- PRIATE
	10	3	7	7	6	2	8			Roy-Chowdhury, et al			3/4/03
		0	1	7	0	2	5	8	9/11/03	Roy-Chowdhury, et al	A1		

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	TRAN- SLATION YES NO
ele	EP	1	0	7	2	2	7	1	1/31/01	Rabbani, et al	A2		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ele		Schoenfeld, Y., et al, "Gaucher's disease: a disease with chronic stimulation of the immune system," <u>Arch Pathol Lab Med</u> 106(8):388-391 (1982)
		Lichtenstein, et al, "Cytokine mRNA in Gaucher Disease," <u>Blood Cells, Molecules and Diseases</u> 23(19):395-401 (1997)
		Barak, V., et al, "Cytokines in Gaucher's Disease," <u>Eur. Cytokine Netw.</u> 10(2):205-210 (1999)
		Hollak, CEM, et al, "Elevated Levels of M-CSF, sCD14 and IL8 in Type 1 Gaucher Disease," <u>Blood Cells, Molecules and Diseases</u> 23(11):201-212 (1997)
		Allen, MJ, et al, "Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10," <u>Q. J. Med.</u> 90(1):19-25 (1997)
		Deibener, J., et al, "Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher's disease," <u>Haematologica</u> 83:479-480 (1998)
		Lachman, et al, "Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological features," <u>Q. J. Med</u> 93:237-244 (2000)
		Kawano, et al, "CD1d-Restricted and TCR-Mediated Activation of V _α 14 NKT Cells by Glycosylceramides," <u>Science</u> 278:1626-1629 (1997)
		Burdin, N., et al, "Selective Ability of Mouse CD1 to Present Glycolipids: α-Galactosylceramide Specifically Stimulates V _α 14 ⁺ NK T Lymphocytes," <u>J. Immunol</u> 161:3271-3281 (1998)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce

(REV. 8-83) Patent and Trademark Office

INFORMATION DISCLOSURE CITATION
(use several sheets if necessary)


Atty. Docket No.
ENZ-64(D2)

Serial No. 10/733,686

Applicants: Ilan, et al

Filed: Dec. 10, 2003

Group: Not yet assigned



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	TRAN- SLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ele	Hollak, et al, "Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease," J. Clin. Invest. 93(3):1288-1292 (1994)
	Ferrari, C., et al, "Immunopathogenesis of hepatitis C virus infection," J. Hepatol 31s1:31-38 (1999)
	Cerny, A., et al, "Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence," Hepatology 30(3):595-601 (1999)
	Rehermann, B., "Cellular immune response to the hepatitis C virus," J. Viral Hepat. 6s1:31-35 (1999)
	Gotsman, I., et al, "Induction of oral tolerance towards hepatitis B envelope antigens in a murine model," Antiviral Research 48:17-26 (2000)
	Akbar, SM, et al, "Low responsiveness of hepatitis B virus-transgenic mice in antibody response to T-cell-dependent antigen: defect in antigen presenting activity of dendritic cells," Immunology 78(3):468-475 (1993)

EXAMINER

Emily Le

DATE CONSIDERED

2/18/06

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce

(REV. 8-83) Patent and Trademark Office

INFORMATION DISCLOSURE CITATION
(use several sheets if necessary)Atty. Docket No.
ENZ-64(D2)

Serial No. 10/733,686

Applicants: Ilan, et al

Filed: Dec. 10, 2003

Group: 1648

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	TRAN- SLATION YES NO
ele	WO 9 9 3 3 4 7 5	7/8/99	Fredman, et al	A1		
EP	0 9 5 7 1 6 1	11/17/99	Koezuka, et al	A1		
EP	0 9 8 8 8 6 0	3/29/00	Taniguchi, et al	A1		
WO	0 3 9 3 2 8 7	11/13/03	Vo-Hoang, et al	A1		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ele	Margalit, M., et al., "Glucocerebroside Treatment Ameliorates Con-A Hepatitis by Inhibition of NKT Lymphocytes: A New Immunomodulatory Tool," Hepatology 38:163A (2003)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.